Candel Therapeutics Inc is a biopharmaceutical company focused on the development of innovative therapeutics for the treatment of cancer
The company specializes in harnessing the power of oncolytic virus technology, which employs genetically modified viruses to selectively target and destroy tumor cells while also stimulating an immune response against cancer. Through its research and development initiatives, Candel aims to provide novel treatment options that enhance patient outcomes and address unmet medical needs in oncology.
Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.
The Dow Jones Industrial Average is down 556 points midday, heading for its worst daily percentage loss since mid January, while the S&P 500 Index and Nasdaq Composite sit firmly in the red as well.
The analyst noted that CAN-2409's early data in prostate cancer suggests the potential for a meaningful breakthrough, given the lack of significant advancements in available treatments.
Candel Therapeutics, Inc. (NASDAQCADL) shares are trading higher Thursday potentially driven by continued momentum following the company's announcement of positive phase 3 trial results for its CAN-2409 viral immunotherapy in prostate cancer patients. Here's what you need to know.
The stock market experienced a wave of optimism on Wednesday, driven by the latest inflation report. The Nasdaq 100 surged 1.7%, achieving a new record high.
